From WikiProjectMed
Jump to navigation Jump to search
Trade namesSolosec, Flagentyl, Sindil, others[1]
Other namesPM 185184, RP 14539
  • 1-(2-Methyl-5-nitro-1H-imidazol-1-yl)propan-2-ol
Clinical data
Drug classNitroimidazole[2]
Main usesBacterial vaginosis[2]
Side effectsVaginal yeast infection, headache, nausea, diarrhea, abdominal pain[2]
WHO AWaReAccess
Routes of
By mouth
Typical dose2 gram[2]
External links
Legal status
Chemical and physical data
Molar mass185.183 g·mol−1
3D model (JSmol)
  • [O-][N+](=O)c1cnc(n1CC(O)C)C
  • InChI=1S/C7H11N3O3/c1-5(11)4-9-6(2)8-3-7(9)10(12)13/h3,5,11H,4H2,1-2H3 checkY

Secnidazole, sold under the brand name Solosec among others, is an antimicrobial used to treat bacterial vaginosis and trichomonas vaginitis.[2][3] It is taken by mouth.[2]

Common side effects include vaginal yeast infection, headache, nausea, diarrhea, and abdominal pain.[2] Other side effects may include Safety in pregnancy and breastfeeding is unclear.[2] It is a nitroimidazole whose mechanism of action is not entirely clear.[2]

Secnidazole was approved for medical use in the United States in 2017.[2] In the United States a single dose costs about 280 USD as of 2021.[4] It has; however, been available in other parts of the world for decades.[5]

Medical uses

It is used to treat bacterial vaginosis.[2] It works in about half of cases.[6]


It is taken as a 2 gram dose.[2] Generally just one dose is used.[2]


It was first made at least as early as 1966.[7]


A course of treatment in the United States costs about 280 USD.[4] The alternative treatment metronidazole costs around 15 USD for a course of treatment.[6]


Effectiveness in the treatment of dientamoebiasis has been reported.[8] It has also been tested against Atopobium vaginae.[9]


  1. Society, Swiss Pharmaceutical (2000). Index Nominum 2000: International Drug Directory. Taylor & Francis. p. 938. ISBN 978-3-88763-075-1. Archived from the original on 2021-10-12. Retrieved 2021-10-11.
  2. 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 "Secnidazole Monograph for Professionals". Retrieved 11 October 2021.
  3. kumar, Sunesh; Padubidri, V. G.; Daftary, Shirish N. (24 July 2018). Howkins & Bourne, Shaw's Textbook of Gynecology, 17edition-EBOOK. Elsevier Health Sciences. p. 365. ISBN 978-81-312-5412-7. Archived from the original on 12 October 2021. Retrieved 11 October 2021.
  4. 4.0 4.1 "Secnidazole Prices and Secnidazole Coupons - GoodRx". GoodRx. Retrieved 11 October 2021.
  5. Nyirjesy, P; Schwebke, JR (April 2018). "Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment". Future microbiology. 13: 507–524. doi:10.2217/fmb-2017-0270. PMID 29327947.
  6. 6.0 6.1 Leggit, Jeffrey C.; Saguil, Aaron (15 August 2019). "Secnidazole (Solosec) for Bacterial Vaginosis". American Family Physician. 100 (4): 242–243. ISSN 0002-838X. Archived from the original on 2 March 2021. Retrieved 11 October 2021.
  7. Elks, J. (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. p. 667. ISBN 978-1-4757-2085-3. Archived from the original on 12 October 2021. Retrieved 11 October 2021.
  8. Girginkardeşler N, Coşkun S, Cüneyt Balcioğlu I, Ertan P, Ok UZ (February 2003). "Dientamoeba fragilis, a neglected cause of diarrhea, successfully treated with secnidazole". Clinical Microbiology and Infection. 9 (2): 110–3. doi:10.1046/j.1469-0691.2003.00504.x. PMID 12588330.
  9. De Backer E, Dubreuil L, Brauman M, Acar J, Vaneechoutte M (May 2010). "In vitro activity of secnidazole against Atopobium vaginae, an anaerobic pathogen involved in bacterial vaginosis". Clinical Microbiology and Infection. 16 (5): 470–2. doi:10.1111/j.1469-0691.2009.02852.x. PMID 19548924.

External links

  • Gillis JC, Wiseman LR (April 1996). "Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis". Drugs. 51 (4): 621–38. doi:10.2165/00003495-199651040-00007. PMID 8706597.